BIOTRONIK won FDA approval for its MultiPole Pacing (MPP) technology to be introduced in the U.S. on its CRT defibrillators (CRT-Ds). It’s designed to address the fact that the hearts of many patients on cardiac resynchronization therapy (CRT) fail to respond properly, and allowing cardiologists more pacing options can help overcome that in many cases. Specifically, the left ventricle can be paced twice per cycle, delivering the pulses either simultaneously or sequentially.
The same BIOTRONIK CRT-Ds that feature MPP also sport the company’s ProMRI capability, which lets patients with the implants receive MRI scans, given certain precautions are taken. This is an important feature for heart failure patients that often end up needing MRI scans. To help reduce the time the implants are in safe mode, they come with technology that lets them detect an MRI machine’s magnetic field, instantly activating the safety mode and turning it off once away from the magnet.
Here are a few of the other features on BIOTRONIK’s CRT implants, according to the company:
- Closed Loop Stimulation – equips the device to respond appropriately to physiologic demands and acute mental stress
- Ultra-High Energy CRT defibrillator – provides up to 42J of energy to meet patient needs on first and every shock
- CRT-DX system – allows full CRT-D therapy with only two leads
- The thinnest leads approved for use in MR conditional CRT systems, including Sentus ProMRI QP, also launched today.
- BIOTRONIK Home Monitoring® – automatically transmits device data daily; proven to reduce mortality in patients with heart failure by 50%3